In one report [22], the eGFR increased from 16.4 ± 1.0 mL/min/1.73 m2 to 26.6 ± 2.2 mL/min/1.73 m2 at one year after an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) was replaced with another antihypertensive agent, such as a calcium channel blocker in stage G4 or -G5 CKD patients, suggesting that the discontinuation of RAS inhibitors can delay the onset of kidney replacement therapy in the advanced CKD patients. The gene discussed is ACE; the disease is chronic kidney disease.